CytomX Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTMX research report →
Range $6 – $6
Price Chart
About the company
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications.
- CEO
- Sean A. McCarthy
- IPO
- 2015
- Employees
- 69
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on CTMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $442.55M
- P/E
- -4.30
- Fwd P/E
- 32.48
- PEG
- 0.03
- P/S
- 30.15
- P/B
- 1.49
- EV/EBITDA
- -4.49
- Div Yield
- 0.00%
- Gross Margin
- 98.21%
- Op Margin
- -676.46%
- Net Margin
- -608.98%
- ROE
- -33.97%
- ROIC
- -29.68%
Latest fiscal year · YoY change
- Revenue
- $76.20M-44.8%
- Gross Profit
- $76.20M-44.8%
- Op Income
- $-22,364,000
- Net Income
- $-17,368,000-154.5%
- EPS
- $-0.15-139.5%
- OCF Growth
- +12.3%
- FCF Growth
- +12.4%
- 52W High
- $8.21
- 52W Low
- $1.87
- 50D MA
- $2.44
- 200D MA
- $3.63
- Beta
- 2.24
- RSI (14)
- 42
- Avg Volume
- 4.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CytomX said Varseta-M remains the clear focus, with a January update coming on dose optimization and a first look at overall survival as the company moves toward a potential registrational study in 2027.· November 5, 2026
- Varseta-M is advancing toward a potential first registrational study in the first half of 2027, with OS intended as the primary endpoint.
- Management is expanding Varseta-M beyond late-line CRC into bevacizumab and chemo combinations, plus new GI tumor cohorts.
- The company highlighted Varseta-M as the only EpCAM-directed ADC in clinical development and said it may be differentiated by its PROBODY platform.
- Cash was $348 million at quarter-end, helped by a $37 million payment from Regeneron, and runway is projected into the second half of 2028.
- A January update is planned to include optimized dosing, safety/efficacy follow-up, and initial overall-survival data from earlier cohorts.
CytomX reported third-quarter 2026 revenue of $1.7 million, down from $6.0 million in the third quarter of 2025, with the decline mainly tied to the end of the Astellas collaboration in Q2 2026. Operating expenses were $25.2 million versus $21.7 million a year ago; R&D was $16.5 million, up $1.2 million, and G&A was $8.7 million, up $2.3 million. The company ended Q3 2026 with $348 million in cash, cash equivalents and investments, versus $330 million at June 30, 2026, including $37 million received from Regeneron. Management said the current balance sheet supports cash runway into the second half of 2028. No EPS figure was provided. Forward-looking items included an integrated Varseta-M update in January, initial bevacizumab-combination data in the first half of 2027, initiation by year-end of a Varseta-M plus bevacizumab/5-FU/leucovorin study in second-line CRC, and initial CX-801 melanoma data in the first half of 2027.
Sean McCarthy framed the quarter as part of a “highly productive year” and repeatedly emphasized urgency around Varseta-M, which he said has the potential to be one of the first monotherapy ADCs in colorectal cancer. He positioned the drug as first-in-class for the EpCAM target and said CytomX is now broadening development into combinations and other EpCAM-expressing GI cancers. His tone was optimistic but measured, with repeated references to the need for more follow-up and regulatory engagement before the next update.
Christopher Ogden said CytomX is maintaining an efficient and flexible cost structure while advancing the Varseta-M program, and he highlighted a cash runway into the second half of 2028. He cited quarter-end cash, cash equivalents and investments of $348 million, including $37 million from Regeneron, and noted total revenue of $1.7 million, operating expenses of $25.2 million, R&D of $16.5 million, and G&A of $8.7 million. He said capital allocation will remain disciplined as the company prioritizes the most compelling Varseta-M opportunities.
Analysts focused heavily on Varseta-M’s path to registration, including why the monotherapy update moved to January, what follow-up is needed, and whether the pivotal study may target third-line-plus or a faster fourth-line setting. Management said the extra time is to allow sufficient safety and efficacy follow-up and regulatory feedback, and reiterated that OS will be the primary endpoint in a randomized study. Questions also centered on the bevacizumab-chemo combination, safety and GI toxicity, with management saying the early phase 1 portion will likely enroll late-line patients before later moving to second-line, and that diarrhea remains the main safety issue to watch as they aim to keep grade 3 diarrhea at 20% or below. Management said the January update will include optimized dosing and a first look at OS, but did not specify the forum or give a chosen dose.
The bullish case from this call is that CytomX believes Varseta-M is differentiated as the only EpCAM ADC in the clinic, with encouraging activity already seen in heavily pretreated CRC patients. Management said the program is moving toward a potential registrational study, while also opening multiple new paths through combination therapy and broader GI indications.
The main risks are that the key monotherapy update has been pushed to January, implying more time is needed for follow-up, dose optimization, and regulatory alignment. The program also still faces safety questions around GI toxicity, especially diarrhea, as it moves into combination regimens where added treatment burden could complicate development and dosing decisions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.1%
- Shares Outstanding
- 218.00M
- Float Shares
- 176.77M
of shares held by institutions
189 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 34.34M | ▲ 1.62M |
| Kynam Capital Management, LP | 21.70M | ▲ 6.69M |
| Blackrock, Inc. | 17.56M | ▲ 12.33M |
| Bank Of America Corp | 15.08M | ▲ 4.88M |
| Perceptive Advisors LLC | 10.44M | ▲ 340.36K |
| State Street Corp | 9.03M | ▼ 2.72M |
| Vanguard Capital Management LLC | 8.53M | ▼ 207.66K |
| Vanguard Group Inc | 8.48M | ▼ 472.22K |
| Point72 Asset Management, L.P. | 7.81M | ▼ 64.36K |
| Wellington Management Group Llp | 5.17M | ▲ 1.59M |
| Geode Capital Management, LLC | 5.09M | ▲ 414.74K |
| Venrock Adviser, LLC | 4.98M | ▼ 5.00M |
Held by 244 ETFs
Biggest fund positions in CTMX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 25 | McCarthy Sean A. | other | 101,793 |
| Nov 6, 25 | McCarthy Sean A. | sell | 101,793 |
| Nov 6, 25 | McCarthy Sean A. | other | 101,793 |
| Aug 3, 26 | Carvajal Alejandra | other | 450,000 |
| Aug 3, 26 | Carvajal Alejandra | other | 100,000 |
| Aug 3, 26 | Carvajal Alejandra | other | 0 |
| Jul 24, 26 | Fuchs Charles S. | other | 118,000 |
| Jul 24, 26 | Fuchs Charles S. | other | 0 |
| Jun 17, 26 | Su Zhen | other | 59,000 |
| Jun 17, 26 | Young Matthew P. | other | 59,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTMX coverage
Recent articles, reports, and earnings notes.
No research on CTMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTMX report →CytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) Critical Analysis
defenseworld.net · Nov 19
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
globenewswire.com · Nov 17
CytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To Shine
seekingalpha.com · Nov 13
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
CytomX Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 5
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 5
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 5
CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials
seekingalpha.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.